Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.46 |
| ▸ | CTSS | P25774 | 10/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071352 | 0.89 | CTSK (0.44) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13615487 | 0.87 | CYP1A2 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13828997 | 0.87 | CYP1A2 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL168105 | 0.87 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL10224757 | 0.87 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL7279368 | 0.87 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL13828745 | 0.87 | CYP1A2 (0.46) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL12486933 | 0.87 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14984731 | 0.87 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL165346 | 0.86 | CYP1A2 (0.44) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-08-31 | — | — | US | disclosed |
| US-7842626-B2 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-11-30 | — | — | US | disclosed |
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113172-A1 | Partially fluorinated compositions and surface active agents | FLNB, FLNA, FSCN1 | CTSK 1579/4885CTSS 2311/4885CA1 3299/4885 |
| US-20230271945-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, APOB, SAAL1 | CTSK 200/4885CTSS 342/4885CA1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.